Riskpilot← Back to searchSign inGet full accessPHARMACEUTICAL ECONSULTING A/S
A/SActiveCVR 30815378Naverland 2, 10.All other professional, scientific and technical activities n.e.c. · NACE 7499Est. 20079 employees
Revenue 2025
DKK 6,1M
+10% vs 2024
EBITDA margin
-19.4%
-48% vs 2024
Equity ratio
48.6%
Financial strength
Net profit 2025
DKK -1,1M
-66% vs 2024
| Revenue | DKK 6,1M | +10% |
| EBITDA | DKK -1,2M | -48% |
| Net profit | DKK -1,1M | -66% |
| Total assets | DKK 10,6M | +20% |
| Equity | DKK 5,2M | -17% |
| Employees | 9 | — |
Legal name
PHARMACEUTICAL ECONSULTING A/S
CVR number
30815378
Legal form
Aktieselskab
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
3. september 2007
Share capital
DKK 500.000
Employees
9 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med et medlem af bestyrelsen eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive virksomhed med salg af konsulentydelser og rådgivning indenfor farmaceutisk industri samt anden efter ledelsens skøn dermed beslægtet virksomhed.
Address
Naverland 2, 10.
Phone
+4543466366
Email
sr@pec-services.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 8.276 | 6.779 | 5.579 | 5.538 | 6.114 |
| Staff expenses | -5.166 | -5.933 | -5.892 | -6.343 | -6.281 |
| EBITDA | 3.110 | 846 | -313 | -805 | -1.189 |
| Depreciation & amort. | -60 | -76 | -82 | -136 | -80 |
| EBIT | 3.050 | 770 | -395 | -941 | -1.268 |
| Net financials | 57 | 237 | 92 | 49 | 23 |
| Profit before tax | 3.108 | 1.007 | -303 | -892 | -1.245 |
| Tax | 688 | 228 | 80 | -248 | -178 |
| Net profit | 2.420 | 780 | -384 | -644 | -1.067 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 19.658 | 8.092 | 7.991 | 8.806 | 10.595 |
| Equity | 6.467 | 7.247 | 6.863 | 6.220 | 5.153 |
| Long-term debt | 0 | 0 | 0 | 249 | 171 |
| Short-term debt | 13.190 | 845 | 1.127 | 2.330 | 5.271 |
| Total debt | 13.190 | 845 | 1.127 | 2.579 | 5.443 |
EBITDA margin
-19.4%
This company
15.8%
Market median
-223% vs market
20212025
Equity ratio
48.6%
This company
38.2%
Market median
+27% vs market
20212025
Return on equity
-20.7%
This company
18.4%
Market median
-213% vs market
20212025
Net profit margin
-17.5%
This company
8.1%
Market median
-316% vs market
20212025
Asset turnover
0.58×
This company
1.12×
Market median
-48% vs market
20212025
Debt / equity
1.06×
This company
0.62×
Market median
-71% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SO Chief Executive Officer | Chief Executive Officer | 2016 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2016 | |
| Board of Directors | 2016 | |
| Former (1) | ||
| Deputy Chairman | 2007 – 2015 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2007 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
RUGAARD HOLDING ApS
PHARMACEUTICAL ECONSULTING A/S Board members of PHARMACEUTICAL ECONSULTING A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Steen Otto Rugaard | Chief Executive Officer | 0 companies |
| Pernille Laurberg Rugaard | Chairman | 0 companies |
| Hanne Laurberg Olesen | Board of Directors | 0 companies |
| Jens Christian Pii Olesen | Deputy Chairman | 0 companies |